Bio Medica Laboratories (NSE:BMLL) Operating Income: ₹ Mil (TTM As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:BMLL Bio Medica Laboratories Ltd NSE:BMLL
18 GF Score
Price ₹146.80
! 7 Warning Signs
View Full Analysis

What is Bio Medica Laboratories Operating Income?

Bio Medica Laboratories NSE:BMLL +1.21% 18 Operating Income is ₹ Mil as of Mar. 2025. GuruFocus rates NSE:BMLL with a GF Score™ of 18/100. The stock has 7 warning signs investors should review.

Bio Medica Laboratories's Operating Income for the six months ended in Mar. 2025 was ₹143.7 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Bio Medica Laboratories's Operating Income for the six months ended in Mar. 2025 was ₹143.7 Mil. Bio Medica Laboratories's Revenue for the six months ended in Mar. 2025 was ₹382.0 Mil. Therefore, Bio Medica Laboratories's Operating Margin % for the quarter that ended in Mar. 2025 was 37.62%.

Bio Medica Laboratories's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bio Medica Laboratories's annualized ROC % for the quarter that ended in Mar. 2025 was 41.99%. Bio Medica Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 63.98%.

Bio Medica Laboratories  (NSE:BMLL) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bio Medica Laboratories's annualized ROC % for the quarter that ended in Mar. 2025 is calculated as:

ROC % (Q: Mar. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2024 ) + Invested Capital (Q: Mar. 2025 ))/ count )
=143.673 * ( 1 - 25.47% )/( (170.581 + 339.391)/ 2 )
=107.0794869/254.986
=41.99 %

where

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=195.308 - 24.624 - ( 0.103 - max(0, 65.559 - 105.517+0.103))
=170.581

Invested Capital(Q: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=391.179 - 51.72 - ( 0.068 - max(0, 169.943 - 310.912+0.068))
=339.391

Note: The Operating Income data used here is one times the annual (Mar. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Bio Medica Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2024  Q: Mar. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=144.702/( ( (87.271 + max(67.096, 0)) + (74.605 + max(223.396, 0)) )/ 2 )
=144.702/( ( 154.367 + 298.001 )/ 2 )
=144.702/226.184
=63.98 %

where Working Capital is:

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(23.359 + 73.669 + 8.386) - (24.624 + 0 + 13.694)
=67.096

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(41.002 + 181.379 + 88.463) - (51.72 + 0 + 35.728)
=223.396

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Mar. 2025) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Bio Medica Laboratories's Operating Margin % for the quarter that ended in Mar. 2025 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2025 )/Revenue (Q: Mar. 2025 )
=143.673/381.952
=37.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Bio Medica Laboratories Operating Income Related Terms

Bio Medica Laboratories Operating Income Historical Data

* Premium members only.

The historical data trend for Bio Medica Laboratories's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio Medica Laboratories Operating Income Chart

Bio Medica Laboratories Annual Data
Trend Mar23 Mar24 Mar25
Operating Income
12.04 45.21 143.67

Bio Medica Laboratories Semi-Annual Data
Mar23 Mar24 Mar25
Operating Income 12.04 45.21 143.67
NSE:BMLL
18GF Score
Bio Medica Laboratories Ltd NSE:BMLL
Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bio Medica Laboratories Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Operating Income for the trailing twelve months (TTM) ended in Mar. 2025 was ₹ Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of ₹ Mil mean?
Bio Medica Laboratories (NSE:BMLL) has a Operating Income of ₹ Mil as of Mar. 2025. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Bio Medica Laboratories and its competitors.
Is Bio Medica Laboratories' Operating Income too high?
Bio Medica Laboratories' current Operating Income is ₹ Mil. Overall, Bio Medica Laboratories has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Bio Medica Laboratories' Operating Income compare to ISRG and BDX?
Bio Medica Laboratories' Operating Income of ₹ Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Medical Devices & Instruments company?
A good Operating Income depends on the Medical Devices & Instruments industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Bio Medica Laboratories and its competitors. Bio Medica Laboratories's current Operating Income is ₹ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Medica Laboratories stock overvalued right now?
Bio Medica Laboratories (NSE:BMLL) has a current Operating Income of ₹ Mil. The current Operating Income is ₹ Mil. Bio Medica Laboratories' overall GF Score™ is 18/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For Bio Medica Laboratories (NSE:BMLL), the current Operating Income is ₹ Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio Medica Laboratories Business Description

Address Sanwer Road, Plot No. 11B-11C, Sector-E, Industrial Area, Industrial Estate - Indore, Indore, MP, IND, 452015
Bio Medica Laboratories Ltd is engaged in the manufacturing of Pharmaceutical Parenteral Formulations. It manufactures generic drugs in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Its products address a wide range of medical needs and preferences. The majority of revenue is derived from the sales of Liquid injections. Geographically, it operates predominantly in India, and internationally, it exports to Afghanistan.
18GF Score

Get the complete analysis for NSE:BMLL

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹146.80
Price